Alterity Therapeutics Limited
Support and Resistance Levels
Past performance
News About ATHE
All events for ATHE
All deals for ATHE
Financial Ratios
Financial Statements
ATHE vs Sector & Peers
About Alterity Therapeutics Limited
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia. Website alteritytherapeutics.com
Headquarters Melbourne, VIC, AU